NEW YORK (GenomeWeb News) – Affymetrix is planning to expand its presence in the genetic analysis market through an “aggressive” merger-and-acquisitions strategy that will likely extend beyond the firm’s foothold in the microarray sector, company officials said recently.
Speaking to investors at the recent Baird Growth Stock Conference in Chicago, Affy CFO John Batty said that the company is seeking to “acquire technology that will allow us to compete in the broader genetic-analysis market.”

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

CNN reports that researchers have tied a new variant to opioid addiction risk.

Organoids derived from patients' tumors may help determine what chemotherapy treatment patients would benefit from, according to New Scientist.

An initiative from GenomeAsia 100K hopes to increase the number of South Asians in genetic research, according to NBC News.

In Science this week: genomic analysis of ancient and modern horses indicates population turnover, and more.